Department of Neuroscience and Trauma, Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, 4, Newark Street, London E1 2AT, UK.
CNS Neurol Disord Drug Targets. 2012 Aug;11(5):624-41. doi: 10.2174/187152712801661310.
For many years, multiple sclerosis (MS) patients have been self-medicating with illegal street cannabis to alleviate symptoms associated with MS. Data from animal models of MS and clinical studies have supported the anecdotal data that cannabis can improve symptoms such as limb spasticity, which are commonly associated with progressive MS, by the modulation of excessive neuronal signalling. This has lead to cannabis-based medicines being approved for the treatment of pain and spasticity in MS for the first time. Experimental studies into the biology of the endocannabinoid system have revealed that cannabinoids have activity, not only in symptom relief but also potentially in neuroprotective strategies which may slow disease progression and thus delay the onset of symptoms such as spasticity. This review appraises the current knowledge of cannabinoid biology particularly as it pertains to MS and outlines potential future therapeutic strategies for the treatment of disease progression in MS.
多年来，多发性硬化症 (MS) 患者一直在自行使用非法街头大麻来缓解与 MS 相关的症状。来自 MS 动物模型的数据和临床研究支持了这样的说法，即大麻可以通过调节过度的神经元信号来改善与进行性 MS 相关的症状，如肢体痉挛。这导致基于大麻的药物首次被批准用于治疗 MS 的疼痛和痉挛。对大麻素系统生物学的实验研究表明，大麻素不仅具有缓解症状的作用，而且可能具有神经保护作用，从而减缓疾病进展，从而延迟痉挛等症状的出现。这篇综述评估了大麻素生物学的现有知识，特别是与多发性硬化症相关的知识，并概述了多发性硬化症疾病进展治疗的潜在未来治疗策略。
